| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology (Drs. Krauss and Miller), Johns Hopkins University; Maryland Center for Eye Care (Dr. Johnson), University of Maryland; and Neuro-Ophthalmology Unit (Dr. Miller), Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD.
Address correspondence and reprint requests to Dr. Gregory L. Krauss, Meyer 2-147, 600 N. Wolfe St., Baltimore, MD 21287.
Objective: To determine the sources of vigabatrin-associated visual disturbances in patients treated for epilepsy.
Background: Vigabatrin is an extremely effective antiepileptic drug that selectively increases brain gamma-aminobutyric acid (GABA). Several patients recently developed constricted visual fields during vigabatrin treatment in the United Kingdom, indicating the possibility of GABA-associated retinal dysfunction.
Methods: Patients with visual symptoms treated chronically with vigabatrin at our center underwent visual evoked potentials (VEP), electroretinograms (ERG), and visual field and ophthalmologic examinations.
Results: Four of 38 patients treated with vigabatrin developed visual symptoms 2 to 40 months after starting the drug. Two patients complained of constricted visual fields and two had blurred vision. ERG demonstrated evidence of bilateral retinal dysfunction consistent with reduced inner retinal cone response in all four patients. Oscillatory potential responses were lost, suggesting impairment of the highly GABAergic amacrine cells. Two of the patients had normal VEPs and minimal findings on clinical ophthalmology examinations despite abnormal ERGs. Abnormal examination findings were narrowed retinal arteries, surface wrinkling retinopathy, and abnormal macular reflexes. One patient also had reduced rod photoreceptor function in the more symptomatic left eye.
Conclusions: Visual field constriction and blurring during vigabatrin therapy is associated with retinal cone system dysfunction. Visual symptoms may represent selective vulnerability of retinas of affected patients to GABAergic effects of vigabatrin. The prevalence and course of retinal changes associated with vigabatrin therapy are important to determine in a larger group of patients.
Received December 3, 1997. Accepted in final form January 20, 1997.
This article has been cited by other articles:
|
|
 |
|
  G. Mirabella, S. Morong, J. R. Buncic, O. C. Snead, W. J. Logan, S. K. Weiss, M. Abdolell, and C. A. Westall Contrast Sensitivity Is Reduced in Children with Infantile Spasms Invest. Ophthalmol. Vis. Sci., August 1, 2007; 48(8): 3610 - 3615. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Werth and G. Schadler Visual field loss in young children and mentally handicapped adolescents receiving vigabatrin. Invest. Ophthalmol. Vis. Sci., July 1, 2006; 47(7): 3028 - 3035. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Wild, C. R. Robson, A. L. Jones, I. A. Cunliffe, and P. E. M. Smith Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer. Invest. Ophthalmol. Vis. Sci., March 1, 2006; 47(3): 917 - 924. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Hammoudi, S. S. F. Lee, A. Madison, G. Mirabella, J. R. Buncic, W. J. Logan, O. C. Snead, and C. A. Westall Reduced Visual Function Associated with Infantile Spasms in Children on Vigabatrin Therapy Invest. Ophthalmol. Vis. Sci., February 1, 2005; 46(2): 514 - 520. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Banin, R. S. Shalev, A. Obolensky, R. Neis, I. Chowers, and V. Gross-Tsur Retinal Function Abnormalities in Patients Treated With Vigabatrin Arch Ophthalmol, June 1, 2003; 121(6): 811 - 816. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. Pearl, K. M. Gibson, M. T. Acosta, L. G. Vezina, W. H. Theodore, M. A. Rogawski, E. J. Novotny, A. Gropman, J. A. Conry, G. T. Berry, et al. Clinical spectrum of succinic semialdehyde dehydrogenase deficiency Neurology, May 13, 2003; 60(9): 1413 - 1417. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G L Krauss, M A Johnson, S Sheth, and N R Miller A controlled study comparing visual function in patients treated with vigabatrin and tiagabine J. Neurol. Neurosurg. Psychiatry, March 1, 2003; 74(3): 339 - 343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S L Hosking, E J Roff Hilton, S J Embleton, and A K Gupta Epilepsy patients treated with vigabatrin exhibit reduced ocular blood flow Br J Ophthalmol, January 1, 2003; 87(1): 96 - 100. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Trevathan Infantile Spasms and Lennox-Gastaut Syndrome J Child Neurol, February 1, 2002; 17(2_suppl): 2S9 - 2S22. [Abstract] [PDF]
|
|
|
|
 |
|
 R Koul, A Chacko, A Ganesh, S Bulusu, and K Al Riyami Vigabatrin associated retinal dysfunction in children with epilepsy Arch. Dis. Child., December 1, 2001; 85(6): 469 - 473. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Sills, P.N. Patsalos, E. Butler, G. Forrest, N. Ratnaraj, and M.J. Brodie Visual field constriction: Accumulation of vigabatrin but not tiagabine in the retina Neurology, July 24, 2001; 57(2): 196 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Ravindran, P Blumbergs, J Crompton, G Pietris, and H Waddy Visual field loss associated with vigabatrin: pathological correlations J. Neurol. Neurosurg. Psychiatry, June 1, 2001; 70(6): 787 - 789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Iannetti, A. Spalice, F. M. Perla, E. Conicella, U. Raucci, and B. Bizzarri Visual Field Constriction in Children With Epilepsy on Vigabatrin Treatment Pediatrics, October 1, 2000; 106(4): 838 - 842. [Abstract] [Full Text]
|
|
|
|
|
|
N. R. Miller Using the electroretinogram to detect and monitor the retinal toxicity of anticonvulsants Neurology, August 8, 2000; 55(3): 333 - 334. [Full Text] [PDF]
|
|
|
|
|
|
G. F. A. Harding, J. M. Wild, K. A. Robertson, S. Rietbrock, and C. Martinez Separating the retinal electrophysiologic effects of vigabatrin: Treatment versus field loss Neurology, August 8, 2000; 55(3): 347 - 352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Johnson, G. L. Krauss, N. R. Miller, M. Medura, and S. R. Paul Visual function loss from vigabatrin: Effect of stopping the drug Neurology, July 12, 2000; 55(1): 40 - 45. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P Hardus, W M Verduin, G Postma, J S Stilma, T T J M Berendschot, and C W M van Veelen Long term changes in the visual fields of patients with temporal lobe epilepsy using vigabatrin Br J Ophthalmol, July 1, 2000; 84(7): 788 - 790. [Abstract] [Full Text]
|
|
|
|
|
|
I. Nousiainen, R. Kälviäinen, and M. Mäntyjärvi Contrast and glare sensitivity in epilepsy patients treated with vigabatrin or carbamazepine monotherapy compared with healthy volunteers Br J Ophthalmol, June 1, 2000; 84(6): 622 - 625. [Abstract] [Full Text]
|
|
|
|
 |
|
 I F Comaish, C Gorman, N R Galloway, K. Manuchehri, A. Midelfart, and L V Wilton Visual field defect associated with vigabatrin BMJ, May 20, 2000; 320(7246): 1403 - 1403. [Full Text]
|
|
|
|
|
|
Vigabatrin Paediatric Advisory Group Guideline for prescribing vigabatrin in children has been revised BMJ, May 20, 2000; 320(7246): 1404 - 1404. [Full Text]
|
|
|
|
|
|
K. Manuchehri, S. Goodman, L. Siviter, and S. Nightingale A controlled study of vigabatrin and visual abnormalities Br J Ophthalmol, May 1, 2000; 84(5): 499 - 505. [Abstract] [Full Text]
|
|
|
|
|
|
N. Fejerman, R. Cersosimo, R. Caraballo, J. Grippo, S. Corral, R. H. Martino, G. Martino, M. Aldao, P. Caccia, M. Retamero, et al. Vigabatrin as a First-Choice Drug in the Treatment of West Syndrome J Child Neurol, March 1, 2000; 15(3): 161 - 165. [Abstract] [PDF]
|
|
|
|
|
|
M C Lawden, T Eke, C Degg, G F A Harding, and J M Wild Visual field defects associated with vigabatrin therapy J. Neurol. Neurosurg. Psychiatry, December 1, 1999; 67(6): 716 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. R. Miller, M. A. Johnson, S. R. Paul, C. A. Girkin, J. D. Perry, M. Endres, and G. L. Krauss Visual dysfunction in patients receiving vigabatrin: Clinical and electrophysiologic findings Neurology, December 1, 1999; 53(9): 2082 - 2082. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. F. Levinson and O. Devinsky Psychiatric adverse events during vigabatrin therapy Neurology, October 22, 1999; 53(7): 1503 - 1503. [Abstract] [Full Text]
|
|
|
|
|
|
R. Kalviainen, I. Nousiainen, M. Mantyjarvi, E. Nikoskelainen, J. Partanen, K. Partanen, and P. Riekkinen Sr. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects Neurology, September 1, 1999; 53(5): 922 - 922. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Sankar and C. G. Wasterlain Is the devil we know the lesser of two evils? Neurology, May 1, 1999; 52(8): 1537 - 1537. [Full Text]
|
|
|
|
|
|
S. Vanhatalo and L. Paakkonen Visual field constriction in children treated with vigabatrin Neurology, May 1, 1999; 52(8): 1713 - 1713. [Full Text] [PDF]
|
|
|
|
|
|
C. F. Arndt, P. Derambure, S. Defoort-Dhellemmes, and J. C. Hache Outer retinal dysfunction in patients treated with vigabatrin Neurology, April 1, 1999; 52(6): 1201 - 1201. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P Osborne, S. W Edwards, E. Hancock, A. L Lux, F. O'Callaghan, T. Johnson, C. R Kennedy, R. W Newton, C. M Verity, S D Lhatoo, et al. Infantile spasms and vigabatrin BMJ, January 2, 1999; 318(7175): 56a - 56. [Full Text]
|
|
|
|
 |
|
 S. T. Herman and T. A. Pedley New Options for the Treatment of Epilepsy JAMA, August 26, 1998; 280(8): 693 - 694. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
